Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer
暂无分享,去创建一个
P. Kantoff | C. Mantzoros | W. Oh | M. Regan | G. Bubley | C. Ryan | O. Sartor | S. Balk | L. Werner | M. Taplin | S. Denmeade | S. Tu | T. Beer | Stephen Duggan | Y. Ko | R. Rittmaster | P. Mathew
[1] M. Dowsett,et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Dowsett,et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] R. Rittmaster,et al. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. , 2008, Urology.
[4] M. Gleave,et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. , 2008, Cancer research.
[5] T. Yap,et al. Targeting CYP17: established and novel approaches in prostate cancer. , 2008, Current opinion in pharmacology.
[6] P. Nelson,et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.
[7] D. Tindall,et al. Type 1 and Type 2 5α-Reductase Expression in the Development and Progression of Prostate Cancer , 2008 .
[8] P. Kantoff,et al. Adrenal Androgen Levels as Predictors of Outcome in Prostate Cancer Patients Treated with Ketoconazole Plus Antiandrogen Withdrawal: Results from a Cancer and Leukemia Group B Study , 2007, Clinical Cancer Research.
[9] M. Ittmann,et al. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. , 2006, Cancer research.
[10] G. Bubley,et al. Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1 , 2006, Proceedings of the National Academy of Sciences.
[11] T. Golub,et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. , 2006, Cancer research.
[12] H. Scher,et al. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] K. Tomer,et al. Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer , 2005, Clinical Cancer Research.
[14] Ingo K Mellinghoff,et al. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. , 2004, Cancer cell.
[15] E. Small,et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Desok Kim,et al. The Androgen Axis in Recurrent Prostate Cancer , 2004, Clinical Cancer Research.
[17] I. Thompson,et al. The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.
[18] F. S. French,et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. , 2001, Cancer research.
[19] B. Freidlin,et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] E. Small,et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. , 1999, Cancer research.
[21] Noah Craft,et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.
[22] I. Thompson,et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. , 1998, The New England journal of medicine.
[23] L. Schwartz,et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] G. Bubley,et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.
[25] Jorma Isola,et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.
[26] J. Geller,et al. Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. , 1984, The Journal of urology.
[27] J. H. Harrison,et al. Bilateral adrenalectomy for palliative treatment of prostatic cancer. , 1972, The Journal of urology.
[28] E. Latulippe,et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. , 2004, The American journal of pathology.
[29] Daniel Gioeli,et al. Ras signaling in prostate cancer progression , 2004, Journal of cellular biochemistry.
[30] G. Bubley,et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. , 1998, The Journal of urology.